Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The efficacy and safety of tislelizumab combined with bevacizumab and second-line chemotherapy in the treatment of RAS-mutant metastatic colorectal cancer: a single arm, phase II study

ABSTRACT: Interventions: Experimental Arm: tislelizumab combined with bevacizumab and second-line chemotherapy Primary outcome(s): 6-month progression free survival (PFS) rate Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 82872 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial [RNA-Seq]

Project description:While patients with microsatellite instable, metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single arm, phase IB/II MEDITREME trial evaluates safety and efficacy of durvalumab plus tremelimumab in combination with mFOLFOX6 chemotherapy in first line, in 57 patients with RAS-mutant unresectable mCRC. Safety was primary objective of phase IB and no safety issue was observed. The primary objective of phase II was efficacy in terms of 3-month PFS in MSS patients, which was met with a 3 month PFS of 90.7% [95% CI: 79.2-96%]. For secondary objective, response rate was 64.5%, median PFS was 8.2 months [95% CI: 5.9–8.6] and overall survival was not reached in MSS patients. Higher tumor mutational burden and a lower degree of genomic instability in responder patients. Integrated transcriptomic analysis underlined that high immune signature, and low epithelio-mesenchymal transition were associated with better outcome. Immunomonitoring showed induction of neoantigen and NY-ESO1 and TERT blood tumor specific T cell response associated with better PFS. The combination of durvalumab-tremelimumab with mFOLFOX6 was tolerable with promising clinical activity in MSS mCRC.

2023-07-05 | GSE235919 | GEO

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial [scRNA-Seq]

2023-07-05 | GSE235917 | GEO

Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial

Project description:A single arm, Phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, and identify pathologic and transcriptomic correlates of response to therapy.

2023-10-19 | GSE241876 | GEO

A single-arm, single-center clinical study of tislelizumab combined with bevacizumab and TAS-102 and SBRT (BETTER) in the treatment of MSS metastatic Colorectal cancer

Project description:Interventions: Combined therapy group:Tislelizumab +TAS-102+ bevacizumab + stereotactic body radiotherapy Primary outcome(s): mPFS;ORR Study Design: Single arm

| 113359 | ecrin-mdr-crc

A single-arm, prospective, Phase II clinical study of surufatinib in combination with tislelizumab in advanced colorectal cancer after third-line treatment failure

Project description:Interventions: Test group:Surufatinib+tislelizumab Primary outcome(s): Progression-free survival Study Design: Single arm

| 39907 | ecrin-mdr-crc

A multicenter Phase II study of Tislelizumab in combination with bevacizumab and chemotherapy in second-line RAS mutated metastatic colorectal cancer

Project description:Interventions: 1:Tislelizumab;1:Bevacizumab;1:mFOLFOX6;1:FOLFIRI Primary outcome(s): safety;Objective response rate Study Design: Single arm

| 41827 | ecrin-mdr-crc